Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT04067713Active Not Recruiting

Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer

Role: collaborator

NCT04962529Unknown

Breast Cancer Liquid Biopsy Trial

Role: collaborator

NCT04241237Unknown

Concordance Between Liquid and Tissue Biopsy

Role: collaborator

NCT02269982Completed

Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY

Role: collaborator

NCT01830426Completed

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

Role: lead

All 6 trials loaded